drugset / Trial / NCT01607385

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

NCT01607385

Phase 1 Completed 56 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235

Timeline

Start
2012-05-18
Primary completion
2012-12-03
Completion
2012-12-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linerixibat Small molecule
Comparator GSK1614235 Unknown